Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study

Biosimilar Versus Originator Pegfilgrastim for Preventing Chemotherapy-Induced Neutropenia: A Phase III Randomized, Multicenter, Evaluator-Blinded, Noninferiority Study

PURPOSEThis study evaluated the efficacy, safety, and immunogenicity of biosimilar pegfilgrastim (PegFilBS) and originator pegfilgrastim (PegFilOR) in patients with stage 2-4 breast cancer.METHODSThis phase III randomized, multicenter, evaluator-blinded, noninferiority study recruited women with sta...

Full description

Bibliographic Details
Main Authors: Ruben D. Kowalyszyn, Luis E. Fein, Martin E. Richardet, Mirta S. Varela, Eduardo Ortiz, Cristian Micheri, Juan J. Zarba, Susana Kahl, Ezequiel Klimovsky, Andrea A. Federico, Jorge H. Cassini, Gustavo Cortese, Nestor Lago
Format: Article
Language:English
Published: American Society of Clinical Oncology 2022-03-01
Series:JCO Global Oncology
Online Access:https://ascopubs.org/doi/10.1200/GO.21.00276

Internet

https://ascopubs.org/doi/10.1200/GO.21.00276

Similar Items